Safety and immunogenicity of mRNA-1345 revaccination at least 12 months following primary vaccination with a licensed protein subunit RSV vaccine.
VaccineSep 8, 2026 (epub)
Mihir Desai, Jose Cardona, Shishir Khetan et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3 clinical trial assessed the safety and immunogenicity of revaccination with mRNA-1345 in adults aged ≥60 years, at least 12 months after initial vaccination with a licensed protein subunit RSV vaccine. The study found that revaccination was well-tolerated, with significant increases in neutralizing antibody titers for both RSV-A and RSV-B observed by Day 29.
Key findings
- Revaccination with mRNA-1345 was well-tolerated with no safety concerns identified.
- Geometric mean titers for RSV-A and RSV-B increased significantly by Day 29 post-revaccination.
- The geometric mean ratio for RSV-A titers was 0.952 (95% CI, 0.847-1.070).
- The geometric mean ratio for RSV-B titers was 1.087 (95% CI, 0.964-1.226).
Why it matters
Understanding the safety and immunogenicity of revaccination strategies is crucial for maintaining effective protection against RSV in older adults, a population at higher risk for severe disease.